Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Pancreatobiliary cancers exhibit high mortality rates.
• Identifying molecular drivers is crucial for developing novel therapies.

Purpose of the Study:

• To catalogue genomic alterations in pancreatobiliary cancers.
• To investigate the role of GATA6 in cancer development and progression.

Main Methods:

• Array-based genomic profiling of exocrine pancreatic and distal bile duct cancers.
• Xenograft expansion to enrich tumor cell fractions.
• Gene expression analysis (mRNA and protein), immunostaining, and siRNA knockdown experiments.

Main Results:

• Identified focal DNA amplifications and deletions, with 18q11.2 gain in 19% of cases.
• GATA6 was the smallest shared amplified region at 18q11.2.
• GATA6 amplification correlated with overexpression and was found in 46% of primary pancreatic cancers.
• GATA6 knockdown reduced proliferation, cell cycle progression, and colony formation in cancer cell lines.

Conclusions:

• GATA6 amplification and overexpression contribute to the oncogenic phenotype of pancreatic cancer cells.
• GATA6 is a candidate lineage-specific oncogene in pancreatobiliary cancer.
• GATA6 represents a potential therapeutic target for novel treatment strategies.